Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis

This study is designed to further strengthen the clinical application evidence of BaidiZiyin Pill and ShenqiYifei Pill in the treatment of tuberculosis. To be included in the initial treatment of pulmonary tuberculosis patients, on the basis of standardized Western medicine treatment, BaidiZiyin Pills and ShenqiYifei Pills will be used to evaluate the clinical efficacy and safety of their products. 1. Evaluate the improvement of symptoms in the adjuvant treatment of newly treated pulmonary tuberculosis with BaidiZiyin Pill and ShenqiYifei Pill. 2. Explore the sputum negative conversion time and sputum negative conversion rate of BaidiZiyin Pill and ShenqiYifei Pill as adjunctive treatments for newly treated pulmonary tuberculosis. 3. Explore the protective effects of BaidiZiyin Pill and ShenqiYifei Pill on adverse reactions caused by chemotherapy.

NCT Number	NCT06403943
Lead Sponsor	Beijing Chest Hospital Collaborators: The First Affiliated Hospital with Nanjing Medical University, Shenyang Tenth People's Hospital, Lanzhou Pulmonary Hospital, Hebei Chest Hospital, Anhui Chest Hospital, Chongqing Public Health, Chengdu Public Health Clinical Center, Guangzhou Chest Hospital., Third People's Court of Shenzhen, Heilongjiang Provincial Institute of Infectious Disease Prevention and Control, Wuhan tuberculosis Hospital, Suzhou Fifth Hospital
Conditions	Adjuvant, Treatment, Tuberculosis
Enrollment	292 participants
Start Date	2023-05-29
Primary Completion	2026-10-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-05-08